Access
To read this story in full you will need to login or make a payment (see right).
Insight
Nature 446, 1000-1007 (26 April 2007) | doi:10.1038/nature05813; Published online 25 April 2007
Search Pubmed for
nature jobs
Faculty Positions
- University of Calgary
- Calgary Canada
Technical Communications Manager
- Nestlé Purina Pet Care
- Vevey, Switzerland
Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines
Danica P. Galoni
1
&
David Y. Gin2
Abstract
Therapeutic vaccines derived from carbohydrate antigen–adjuvant combinations are a promising approach for cancer immunotherapy. One of the critical limitations in this area is access to sufficient quantities of tumour-associated carbohydrate antigens and glycoconjugate adjuvants. At present, availability of the complex oligosaccharide constructs that are needed for the systematic design and evaluation of novel vaccine formulations relies on de novo chemical synthesis. The use of both state-of-the-art and emerging glycosylation technologies has led to significant advances in this field, allowing the clinical exploration of carbohydrate-based antigens in the treatment of cancer.
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
